Examining long-acting injectable antipsychotic (depot) medication in the elderly: a five-year retrospective cross-sectional study evaluating depot use in an Australian psychogeriatric service

Abstract

Objective:

The primary aim was to examine the use of long-acting injectable (LAI) antipsychotic (depot) medication in a cohort of older patients in a community psychogeriatric service.

Method:

From 2014 to 2018, all patients who were on LAIs each year were analysed for various characteristics including their profile, type of LAI used, dose and relapse rates related to switching, ceasing and community treatment order (CTO) use.

Results:

A total of 880 patients were managed by the service with 142 recorded cases of LAI use in total over the 5 years (16.1%). Second-generation antipsychotics (SGAs) outnumbered first-generation antipsychotics (FGAs) by 2:1, with a trend of increasing use of SGA LAIs. The most commonly used LAI was Paliperidone monthly injection (PP1M) (50.7%). Lower than usual adult chlorpromazine equivalent daily doses of LAIs were used. The relapse rate while on a LAI was 13.4%. Moreover, 54.9% of the patients on LAIs were on a CTO. Relapse rates were lower on LAIs in combination with a CTO (7.7%).

Conclusions:

LAIs, especially the SGAs, are increasingly used in our service. In combination with a CTO, LAIs are an effective treatment in reducing relapse rates in the elderly.

Keywords

aged elderly depot long-acting injectable antipsychotic schizophrenia

Get full access to this article

View all access options for this article.

References

Masand

. Side effects of antipsychotics in the elderly. J Clin Psychiatry 2000; 61: 43–49; discussion 50-41.

Masand

Gupta

. Long-acting injectable antipsychotics in the elderly. Drugs Aging 2003; 20: 1099–1110.

Lasser

Bossie

Zhu

, et al. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry 2004; 19: 898–905.

Lin

Chen

Chan

, et al. A Comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia. Am J Geriatr Psychiatry 2020; 28: 23–30.

Parellada

Kouniakis

Siurkute

, et al. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol 2010; 25: 149–154.

Rado

Janicak

. Pharmacological and clinical profile of recently approved second-generation antipsychotics. Drugs Aging 2012; 29: 783–791.

Raj

Lewis

Macfarlane

. Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia. Case Rep 2015; 2015: bcr2015212149.

Stip

Lachaine

. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Ther Adv Psychopharmacol 2018; 8: 287–301.

Taylor

Barnes

Young

. The Maudsley prescribing guidelines in psychiatry. John Wiley & Sons, 2018, p. 14,15.

10.

Patel

Arista

Taylor

, et al. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res 2013; 149: 141–148.

11.

Barnes

Shingleton-Smith

Paton

. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry 2009; 195: s37–s42.

12.

West

Marcus

Wilk

, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008; 34: 995–1001.

13.

Jablensky

McGrath

Herrman

, et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry 2000; 34: 221–236.

14.

Altamura

Mauri

Girardi

, et al. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. Int J Clin Pharmacol Res 1990; 10: 223–228.

15.

Howard

Levy

. Which factors affect treatment response in late paraphrenia? Int J Geriatr Psychiatry 1992; 7: 667–672.

16.

Raskind

Alvarez

Herlin

. Fluphenazine enanthate in the outpatient treatment of late paraphrenia. J Am Geriatr Soc 1979; 27: 459–463.

17.

Burke

Shome

. Early intervention in schizophrenia in the elderly. Aust N Z J Psychiatry 1998; 32: 809–814.

18.

Davis

Chen

. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192–208.

19.

Alphs

Nasrallah

Bossie

, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmacol 2016; 31: 202–209.